Toward the legalization, regulation and restriction of access to marijuana: Discussion paper – 4. Conclusion and references

• 1.Introduction
• 2. Background
• 3. Discussion Issues: Elements of a New System
• 3.1 Minimizing harms of use
• 3.2 Establishing a Safe and Responsible Production System
• 3.3 Designing an appropriate distribution system
• 3.4 Enforcing public safety and protection
• 3.5 Accessing Marijuana for Medical Purposes
• 4. Conclusion and References

4. Conclusion and References

Conclusion

The subject of marijuana access and use is important, sensitive and complex, with issues and implications spanning health, public safety, and social and criminal justice policy domains. This discussion document presents key considerations for Canada's approach to designing a system to legalize, regulate and restrict access to marijuana. It will be important to determine the most effective approaches to designing and implementing an effective system.

Addressing legalization requires input from all sectors and Canadians. In order to shape the best long-term approach for Canadians, engaging with experts, provinces and territories, and Canadians is key.

This document will be used to form the basis of discussions with provinces, territories and experts. All stakeholders - from governments and experts to Canadians - are invited to submit their views through the website [LINK].

Based on the comments received through engagement, the Task Force will draft a report that will be submitted to the Government to inform decisions on how best to legalize, regulate and restrict access to marijuana.

References

• Bowes et al. (2013) Lifecourse SEP and tobacco and cannabis use European Journal of Public Health 23(2): 322-7.
• Calvignioni et al. (2014) Neuronal substrates and functional consequences of prenatal cannabis exposure European Child and Adolescent Psychiatry 23(10): 931-41.
• Canadian Centre on Substance Abuse. (2015) Cannabis Regulation: Experiences, Impacts and Lessons Learned In Colorado.
• Centre for Addiction and Mental Health (CAMH). Cannabis Policy Framework. Toronto, ON: CAMH; 2014 Oct.
• Chadwick et al. (2013) Cannabis use during adolescent development: susceptibility to psychiatric illness Frontiers in Psychiatry 4: 129.
• Degenhardt and Hall (2012) Extent of illicit drug use and dependence, and their contribution to the global burden of disease The Lancet 379(9810): 55-70.
• Degenhardt et al. (2013) The global epidemiology and contribution of cannabis use and dependence to the global burden of disease: results from the GBD 2010 study PLoS One 8(10): e76635.
• Devinsky O, Cilio MR, Cross H, Fernandez-Ruiz J, French J, Hill J, et al. Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia. 2014 Jun;55(6):791–802.
• El Sohly et al. (2000) Potency trends of delta-9 THC and other cannabinoids in confiscated marijuana from 1980-1997. Journal of Forensic Science 45(1): 24-30.
• EMCDDA Annual Report (2010) Risk Factors for Cannabis Initiation and Dependence http://www.emcdda.europa.eu/online/annual-report/2010/boxes/p45
• Fergusson et al. (2008) Cannabis use and later life outcomes Addiction 103(6): 969-76.
• George, T., & Vaccarino, F. (Eds.). (2015). Substance abuse in Canada: The Effects of Cannabis Use during Adolescence. Ottawa, ON: Canadian Centre on Substance Abuse.
• Hall W, Degenhardt L. The adverse health effects of chronic cannabis use. Drug Test Anal. 2014 Jan–Feb;6(1–2):39–45.
• Hall (2015) What has research over the past two decades revealed about the adverse health effects of recreational cannabis use? Addiction 110(1): 19-35.
• Hartman RL, Brown TL, Milavetz G, Spurgin A, Pierce RS, Gorelick DA, et al. Cannabis effects on driving lateral control with and without alcohol. Drug Alcohol Depend. 2015 Sep 1;154:25–37.
• Hartman RL, Brown TL, Milavetz G, Spurgin A, Gorelick DA, Gaffney G, et al. Controlled vaporized cannabis, with and without alcohol: Subjective effects and oral fluid-blood cannabinoid relationships. Drug Test Anal. 2015 Aug 10. doi: 10.1002/dta.1839.
• Health Canada. Consumer Information—Cannabis (Marihuana, marijuana). Ottawa, ON: Health Canada; 2015 Dec. Available from: http://www.canada.ca/content/dam/hc-sc/migration/hc-sc/dhp-mps/alt_formats/pdf/marihuana/info/cons-eng.pdf
• Health Canada. Information for Health Care Professionals—Cannabis (marihuana, marijuana) and the cannabinoids. Ottawa, ON: 2013 Feb. Available from: http://www.canada.ca/content/dam/hc-sc/migration/hc-sc/dhp-mps/alt_formats/pdf/marihuana/med/infoprof-eng.pdf
• Heishman SJ, Arasteh K, Stitzer ML. Comparative effects of alcohol and marijuana on mood, memory, and performance. Pharmacol Biochem Behav. 1997 Sep;58(1):93–101.
• Horwood et al. (2010) Cannabis use and educational achievement: findings from three Australasian cohort studies. Drug and Alcohol Dependence 110(3): 247-53.
• Hussain SA, Zhou R, Jacobson C, Weng J, Cheng E, Lay J, et al. Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox-Gastaut syndrome. Epilepsy Behav. 2015 Jun;47:138–41.
• Husni et al. (2014) Evaluation of Phytocannabinoids from High Potency Cannabis sativa using In Vitro Bioassays to Determine Structure-Activity Relationships for Cannabinoid Receptor 1 and Cannabinoid Receptor 2. Medicinal Chemistry Research 23(9): 4295-4300.
• Leyton, M., & Stewart, S. (Eds.). (2014). Substance abuse in Canada: Childhood and adolescent pathways to substance use disorders. Ottawa, ON: Canadian Centre on Substance Abuse.
• Loflin and Earlywine (2014) A new method of cannabis ingestion: the danger of dabs? Addictive behaviors 39(10): 1430-3.
• Marihuana for Medical Purposes Regulations, SOR/2013-119. Available from: http://www.laws-lois.justice.gc.ca/eng/regulations/SOR-2013-119/
• Meier et al. (2012) Persistent cannabis users show neuropsychological decline from childhood to midlife. Proceedings of the National Academy of Sciences 109(40): E2657-64.
• Naftali T, Bar-Lev Schleider L, Dotan I, Lansky EP, Sklerovsky Benjaminov F, Konikoff FM. Cannabis induces a clinical response in patients with Crohn's disease: A prospective placebo-controlled study. Clin Gastroenterol Hepatol. 2013 Oct;11(10):1276–80.
• Porter BE, Jacobson C. Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy. Epilepsy Behav. 2013 Dec;29(3):574–7.
• Public Health Agency of Canada. (2016) The Chief Public Health Officer's Report on the State of Public Health in Canada, 2015: Alcohol Consumption in Canada.
• Radhakrishnan et al. (2014) Gone to Pot—A review of the association between cannabis and psychosis Frontiers in Psychiatry 5: 54.
• Rigucci et al (2015) Effect of high-potency cannabis on corpus callosum microstructure Psychological Medicine Nov 27: 1-14.
• Rogosch et al. (2010) From child maltreatment to adolescent cannabis abuse and dependence: a developmental cascade model Development and Psychopathology 22(4): 883-97
• Sewell RA, Poling J, Sofuoglu M. The effects of cannabis compared with alcohol on driving. Am J Addict. 2009;18(3):185–93.
• Silins et al. (2014) Young adult sequelae of adolescent cannabis use: an integrative analysis The Lancet Psychiatry 1(4): 286-93.
• UNICEF Office of Research (2013). 'Child Well-being in Rich Countries: A comparative overview', Innocenti Report Card 11, UNICEF Office ofResearch, Florence.
• UNODC, World Drug Report 2012 (United Nations publication, Sales No. E.12.XI.1).
• Vanyukov et al. (2012) Common liability to addiction and "gateway hypothesis": theoretical, empirical and evolutionary perspective Drug and Alcohol Dependence 123 Suppl 1 S3-17.
• Volkow ND, Baler RD, Compton WM, Weiss SRB. Adverse health effects of marijuana use. New Engl J Med. 2014 Jun 5;370(23):2219–27.

Document navigation

• Previous